Endopredict®
GAIN CERTAINTY IN BREAST CANCER TREATMENT WITH ACTIONABLE RESULTS
Using an accurate predictive and prognostics test recommended by the UK National Institute of Clinical Excellence (NICE) with Level of evidence 1A in ESMO guidelines.
Endopredict® helps you detect risk of recurrence for ER positive/HER2 negative early-stage breast cancer
Gene expression tests are guiding critical treatment decisions in early-stage breast cancer. Using genomic testing for breast cancer recurrence, you can avoid under or over treatment and the life-changing impact these choices can have on woman's life - now and in years to come.
EndoPredict Breast Cancer Prognostic Test is the most accurate expression test for early-stage breast cancer recurrence to help you make treatment decisions for your eligible ER positive/HER2 negative primary invasive breast cancer patients.
EndoPredict is a second generation test that incorporates more than other tests.
.png)
The EPclin Risk Score combines clinical and molecular factors for enhanced prognostic performance, supporting accurate decisions.
The 12-gene Molecular Score monitors for genes selected tom optimize prediction of early and late recurrence (0-15 years) - this is why EndoPredict provides the most accurate long-term recurrence risk for breast cancer.
EndoPredict helps you by answering these questions:
Is chemotherapy right for you? EndoPredict shows your individual risk of breast cancer distant recurrence in the next 10 years if you were treated by hormone therapy alone. It also estimates how much chemotherapy is likely to reduce the risk of your breast cancer distant recurrence. As tumors treated with chemotherapy could also return, the benefits of chemotherapy may not outweigh the potential side-effects for you.
EndoPredict shows your risk of your breast cancer recurrence in the 10 years after you received 5 years of hormone therapy. This can help you and your doctor to decide if 5 years of hormone therapy is enough or if extended hormone therapy should be considered. this information is provided before you start treatment with drugs, so you can make treatment decisions for the present and future.
What is the risk of my cancer spreading outside of the breast?
EndoPredict is the most accurate prognostic test to guide early treatment decisions, providing an individual risk of breast cancer recurrence at 10 years.
What is absolute chemotherapy benefit at 10 years?
Some women benefit more from chemotherapy than others - EndoPredict predicts the personalized benefit from chemotherapy for every patient to guide decision making in treatment.
Will extended endocrine therapy be needed?
EndoPredict is the only test to predict breast cancer recurrence risk up to 15 years, helping clinicians decide if the patient can safely stop endocrine therapy at 5 years.
THE ENDOPREDICT TEST IS PART OF THE UK NEQAS (EXTERNAL QUALITY ASSESSMENT SCHEME).
How to perform the EndoPredict test?
EndoPredict Breast Cancer Prognostic Test is a second generation gene expression breast cancer recurrence test available for local pathology labs to perform, allowing clinicians fast access to results. Our pathology lab partners offer EndoPredict across the world.
Sampling
- The test is performed on FFPE tumor tissue from biopsy or surgical specimens. Either a tumor block or slides are suitable.
- The tumor should represent at least 30% of the sample.
RNA isolation
- Can be performed manually or automatically, with a turnaround time of 3 hours per 12 samples.
Analysis
- Rt-qPCR can be run on one of three different PCR platforms (VERSANT kPCR [Siemens Healthcare]; QuanStudio DX [Thermo Fisher]; QuanStudio 5 DX [Thermo Fisher].
- Up to 4 samples can be run with one PCR instrument with the total laboratory time less than 8 hours, or up to 12 samples in 2 days.
Result
- The result report (including quality control) is generated using a web-based software - see the EndoPredict report generator.
- A report is generated in less than 15 minutes.
DEEP DIVE INTO THE TEST
ENDOPREDICT IN A NUTSHELL
After diving into the details of EndoPredict on this page, you might still have questions. This video aims to wrap it all up, offering you critical insights in an easy-to-understand format. Find out how EPclin Risk Score isn't just a number - it's a key that can unlock personalized treatment options for the patient. Ideal for those seeking direct answers, this video aims to inform in patients paths forward.